Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separatio… Read more
Nanologica AB (NICA) - Net Assets
Latest net assets as of December 2025: Skr22.64 Million SEK
Based on the latest financial reports, Nanologica AB (NICA) has net assets worth Skr22.64 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr88.11 Million) and total liabilities (Skr65.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr22.64 Million |
| % of Total Assets | 25.7% |
| Annual Growth Rate | 14.75% |
| 5-Year Change | -56.11% |
| 10-Year Change | 2.77% |
| Growth Volatility | 653.28 |
Nanologica AB - Net Assets Trend (2012–2025)
This chart illustrates how Nanologica AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanologica AB (2012–2025)
The table below shows the annual net assets of Nanologica AB from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr22.64 Million | -69.45% |
| 2024-12-31 | Skr74.11 Million | +4004.74% |
| 2023-12-31 | Skr-1.90 Million | -102.59% |
| 2022-12-31 | Skr73.16 Million | +41.79% |
| 2021-12-31 | Skr51.60 Million | -44.50% |
| 2020-12-31 | Skr92.97 Million | +2155.89% |
| 2019-12-31 | Skr4.12 Million | -82.62% |
| 2018-12-31 | Skr23.71 Million | +1123.13% |
| 2017-12-31 | Skr1.94 Million | -91.20% |
| 2016-12-31 | Skr22.03 Million | -8.72% |
| 2015-12-31 | Skr24.14 Million | +195.79% |
| 2014-12-31 | Skr8.16 Million | -23.43% |
| 2013-12-31 | Skr10.66 Million | +181.53% |
| 2012-12-31 | Skr3.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanologica AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41752281100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.51 Million | 19.90% |
| Other Components | Skr442.05 Million | 1952.10% |
| Total Equity | Skr22.64 Million | 100.00% |
Nanologica AB Competitors by Market Cap
The table below lists competitors of Nanologica AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SUREFIRE RES
F:GBL
|
$1.16 Million |
|
JADE ROAD INVESTMENTS LTD
F:1CP0
|
$1.16 Million |
|
Commander Resources Ltd
PINK:CMDRF
|
$1.16 Million |
|
Escalon Medical Corp
OTCQB:ESMC
|
$1.16 Million |
|
Blue Chip India Limited
NSE:BLUECHIP
|
$1.16 Million |
|
WORKDAY-A
MU:W7D
|
$1.16 Million |
|
1847 Holdings LLC
NYSE MKT:EFSH
|
$1.16 Million |
|
Impac Mortgage Holdings Inc
PINK:IMPM
|
$1.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanologica AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 74,112,000 to 22,645,000, a change of -51,467,000 (-69.4%).
- Net loss of 51,289,000 reduced equity.
- New share issuances of 38,000 increased equity.
- Other comprehensive income increased equity by 999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-51.29 Million | -226.49% |
| Share Issuances | Skr38.00K | +0.17% |
| Other Comprehensive Income | Skr999.00 | +0.0% |
| Other Changes | Skr-217.00K | -0.96% |
| Total Change | Skr- | -69.44% |
Book Value vs Market Value Analysis
This analysis compares Nanologica AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.12x to 1.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr3.39 | Skr0.40 | x |
| 2013-12-31 | Skr7.40 | Skr0.40 | x |
| 2014-12-31 | Skr2.38 | Skr0.40 | x |
| 2015-12-31 | Skr6.61 | Skr0.40 | x |
| 2016-12-31 | Skr5.84 | Skr0.40 | x |
| 2017-12-31 | Skr0.42 | Skr0.40 | x |
| 2018-12-31 | Skr1.43 | Skr0.40 | x |
| 2019-12-31 | Skr0.24 | Skr0.40 | x |
| 2020-12-31 | Skr3.84 | Skr0.40 | x |
| 2021-12-31 | Skr1.82 | Skr0.40 | x |
| 2022-12-31 | Skr2.40 | Skr0.40 | x |
| 2023-12-31 | Skr-0.05 | Skr0.40 | x |
| 2024-12-31 | Skr1.50 | Skr0.40 | x |
| 2025-12-31 | Skr0.26 | Skr0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanologica AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -226.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -242.77%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 3.89x
- Recent ROE (-226.49%) is below the historical average (-195.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -133.01% | -141.30% | 0.55x | 1.71x | Skr-5.41 Million |
| 2013 | -105.89% | -212.36% | 0.34x | 1.46x | Skr-11.01 Million |
| 2014 | -180.42% | -894.90% | 0.08x | 2.40x | Skr-15.54 Million |
| 2015 | -59.20% | -438.02% | 0.10x | 1.36x | Skr-16.70 Million |
| 2016 | -101.93% | -1122.76% | 0.06x | 1.45x | Skr-24.66 Million |
| 2017 | -1036.69% | -772.94% | 0.10x | 13.37x | Skr-20.29 Million |
| 2018 | -88.11% | -503.92% | 0.12x | 1.45x | Skr-23.26 Million |
| 2019 | -521.07% | -209.97% | 0.24x | 10.26x | Skr-21.89 Million |
| 2020 | -26.70% | -153.86% | 0.11x | 1.57x | Skr-34.12 Million |
| 2021 | -97.16% | -388.20% | 0.13x | 1.91x | Skr-55.29 Million |
| 2022 | -75.30% | -3542.77% | 0.01x | 2.11x | Skr-62.41 Million |
| 2023 | 0.00% | -5208.39% | 0.02x | 0.00x | Skr-74.97 Million |
| 2024 | -88.55% | -451.43% | 0.10x | 1.93x | Skr-73.04 Million |
| 2025 | -226.49% | -242.77% | 0.24x | 3.89x | Skr-53.55 Million |
Industry Comparison
This section compares Nanologica AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $106,934,177
- Average return on equity (ROE) among peers: -113.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanologica AB (NICA) | Skr22.64 Million | -133.01% | 2.89x | $1.16 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.39 Million |
| Abliva AB (ABLI) | $70.72 Million | -135.06% | 0.24x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $25.35 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $4.79 Million |
| Active Biotech AB (ACTI) | $646.03 Million | 0.00% | 0.35x | $3.42 Million |
| Alzinova AB (ALZ) | $59.11 Million | -10.49% | 0.07x | $3.99 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $12.21 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $4.76 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $757.29K |
| Biosergen AS (BIOSGN) | $22.79 Million | -149.37% | 0.48x | $2.84 Million |